• Raised A$2.668m through oversubscribed Share Purchase Plan
• Funds to support strategic and cost optimisation initiatives
• Placement of A$375,000 to directors subject to shareholder approval

MedAdvisor Limited, a global leader in pharmacy-driven patient engagement solutions, has announced the successful completion of its Share Purchase Plan (SPP). The SPP was launched following the company's recent A$5 million placement to institutional and sophisticated investors. Through the SPP, eligible shareholders were able to subscribe for up to A$30,000 worth of new shares at A$0.10 per share. The company received valid SPP applications totalling A$2.668 million and will accept all valid applications received. The SPP shares will be issued on 16 May 2025 and will rank equally with the company's existing fully paid ordinary shares. The funds raised through the SPP and the previous placement will support the continued execution of MedAdvisor's strategic and cost optimisation initiatives and provide additional working capital to drive sustainable growth. The company also noted that the placement included an amount of A$375,000 committed by MedAdvisor directors, with the issue of these shares subject to shareholder approval at an Extraordinary General Meeting (EGM) expected to be held on 27 June.